A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 850
- 主要终点
- Rate of Asthma Exacerbations Over the 48 Week Treatment Period
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the treatment of subjects aged 12-75 years old diagnosed with moderate to severe asthma who are inadequately controlled with high-dose inhaled corticosteroids (ICS)+ long-acting beta-agonists (LABA) with or without additional controller therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form and an informed assent, if applicable
- •Be between the ages of 12 to 75 years
- •Have had a history of moderate to severe asthma for at least one year prior to screening
- •Have had treatment with a stable regimen of of salmeterol 50 µg twice a day (BID) or formoterol 12 µg BID for at least 8 weeks prior to screening
- •Have had treatment with a stable regimen of high-dose inhaled corticosteroids (ICS) for at least 8 weeks prior to screening
- •Have inadequately controlled asthma
- •Have had at least one asthma exacerbation requiring systemic corticosteroid rescue in the 12 months prior to the screening visit while receiving treatment with high-dose ICS
- •Have less than 10 pack-years smoking history
- •Have a positive skin test for or a positive, in vitro response to one relevant perennial aeroallergen documented within the 12 months prior to screening
- •If a subject has not had a positive skin test or in vitro reactivity in the 12 months prior to screening, the subject must demonstrate a positive response to at least one relevant perennial aeroallergen in a skin or in vitro test prior to randomization
- •Female subjects of childbearing potential must use an effective method of contraception from screening through their duration of participation in the study
- •For the collection of additional blood samples for future research (optional), provide signed consent and an informed assent, if applicable.
排除标准
- •Have had an asthma exacerbation requiring intubation within 12 months prior to screening
- •Have active lung disease other than asthma
- •Have had an asthma exacerbation requiring treatment with the addition of systemic (oral or intravenous) corticosteroids or an increase in systemic corticosteroids within 30 days prior to screening
- •Require chronic immunosuppressive therapy including cyclosporine, methotrexate, etc.
- •Have significant medical illness other than asthma
- •Have taken methotrexate, gold salts, cyclosporine, or macrolide antibiotics, within 3 months prior to screening
- •Have taken other investigational drugs within 30 days prior to screening
- •Have been treated with Xolair within the 12 months prior to screening
- •Have a history of drug or alcohol abuse that, in the judgment of the investigator, may put the subject at risk for being unable to participate fully in the study for the duration of the study
- •Have elevated serum IgE levels for reasons other than allergy
- •Are pregnant or lactating
研究组 & 干预措施
Xolair
The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: omalizumab (Xolair) (Drug)
Xolair
The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: corticosteroids (Drug)
Xolair
The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: long-acting beta-agonists (Drug)
placebo
The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: placebo (Drug)
placebo
The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: corticosteroids (Drug)
placebo
The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
Participants were permitted to use albuterol as rescue medicine throughout the study.
干预措施: long-acting beta-agonists (Drug)
结局指标
主要结局
Rate of Asthma Exacerbations Over the 48 Week Treatment Period
时间窗: 48 weeks
A protocol-defined asthma exacerbation was defined as worsening of asthma symptoms requiring treatment with systemic corticosteroids for 3 or more days; for patients receiving long-term oral corticosteroids, an exacerbation was a 20 mg or more increase in average daily dose of oral prednisone (or a similar dose of another systemic corticosteroid). The rate of protocol-defined asthma exacerbations, normalized by subject-time at risk and computed over the 48 week treatment period in each treatment group.
次要结局
- Number of Participants Assessed for Frequency and Severity of Treatment-emergent Adverse Events(Week 48)
- Change From Baseline in Total Asthma Symptom Scores(Baseline and Week 48)
- Change From Baseline in the Number of Puffs Per Day of Beta Agonist Rescue Medication(Baseline and Week 48)
- Change From Baseline in Overall Asthma-related Quality of Life(Baseline and Week 48)